PercuSurge raises $15 million in financing:
This article was originally published in Clinica
Executive Summary
PercuSurge has completed a private placement, raising $15 million. The Sunnyvale, California-based company plans to use the fresh funds in efforts to gain FDA approval for its GuardWire Plus, for use in diseased saphenous vein grafts. The system helps contain and remove excess particles and blood clots that often get dislodged during the treatment of atherosclerosis. Investor Growth Capital led the financing. Its managing director, Stephen Campe, said: "We performed an extensive amount of due diligence during our evaluation of this investment and see PercuSurge as a clear emerging leader in this field."